Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: The end of an era?

International Journal of Antimicrobial Agents

Volumn 21, Issue 6, 2003, Pages 521-524

  Nathwani, Dilip ^a   Tillotson, Glenn S ^b  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; CLOXACILLIN; RIFAMPICIN; VANCOMYCIN;

BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; DRUG SENSITIVITY; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; NOTE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE;

EID: 0037507262     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00046-3     Document Type: Note

References (37)

1. Karchmer A.W. Staphylococcus aureus and vancomycin: the sequel. Ann. Intern. Med. 115:1991;739-740.
2. Diekema D.J., Pfaller M.A., Schmitz F.J., et al. Survey of infections due to Staphylococcus species: frequency of occurrence and the antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32:(Suppl. 2):2001;S114-S132.
3. Gorak E.J., Yamada S.M., Brown J.D., et al. Community acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin. Infect. Dis. 29:1999;797-800.
4. Whitby M., McLaws M.L., Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med. J. Aust. 175:1992;264-267.
5. Kollef M.H., Fraser V.J. Antibiotic resistance in the intensive care unit setting. Ann. Intern. Med. 134:2001;298-314.
6. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically unwell patients. Chest. 115:1999;462-474.
7. Rello J., Gallego M., Mariscal D., et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156:1997;196-200.
8. Bradley S.F., Terpenning M.S., Ramsey M.A., et al. Methicillin-resistant Staphylococcus aureus: colonization and infection in a long-term care facility. Ann. Intern. Med. 115:1991;417-422.
9. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect. Dis. 1:2001;147-155.
10. Chambers HF. Methicillin resistance in Staphylococci: molecular and biochemical basis and clinical implications, Clin. Microbiol. Rev. 1997;10:781-91.
11. Cantoni L., Glauser M.P., Bille J. Comparative efficacy of daptomycin, vancomycin, cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and the role of test conditions in this determination. Antimicrob. Agents Chemother. 34:1990;2348-2353.
12. Small P.M., Chambers H.F. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 115:1990;674-680.
13. Tam VH, Jumbe NL, Miller MH. A comparative study of vancomycin and β-lactams in the treatment of staphylococcal bacteraemia in haemodialysis (HD) patients. 38th ICAAC, San Francisco, CA, 1999 (Abstract Number 1095).
14. Fortun J., Navas E., Martinez-Beltran J., et al. Short course therapy for right side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. Clin. Infect. Dis. 33:2001;120-125.
15. Rello J., Torres A., Ricard M., et al. Ventilator-associated pneumonia by Staphylococcus aureus. Am. J. Respir. Crit. Care Med. 150:1994;1545-1549.
16. Gonzalez C., Rubio M., Romero-Vivas J., et al. Bacteraemic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis. 29:1999;1171-1177.
17. Georges H., Leroy O., Alfandari S., et al. Pulmonary disposition of vancomycin in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;385-388.
18. Lamer C., de Beco V., Soler P., Calvat S., et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother. 37:1993;281-286.
19. Conte J.E., Golden J.A., Kipps J., Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:2002;1475-1480.
20. Stevens D.L., Smith L.G., Maureen B., et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 44:2000;3408-4313.
21. Bodi M., Ardanuy C., Rello J. Impact of Gram-positive resistance on outcome of nosocomial pneumonia. Crit. Care Med. 29:(Suppl. 4):2001;N82-N86.
22. Mella S., Sepulveda M., Bello H., et al. Cloxacillin and vancomycin bactericidal action against oxacillin-susceptible Staphylococcus aureus. Rev. Med. Chil. 129:2001;224-226.
23. Chambers HF. Parenteral antibiotics for treatment of bacteraemia and other serious staphylococcal infections, In: Crossley KB, Archer GL, editors. The Staphylococcus in Human Disease. New York: Churchill Livingstone, Inc., 1997;p. 583-601.
24. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampicin in methicillin-resistant Staphylococcus aureus endocarditis, Ann. Intern. Med. 1991;115:674-80.
25. Faville R.J. Jr., Zaske D.E., Kaplan E.L., et al. Staphylococcus aureus endocarditis: combined therapy with vancomycin and rifampicin. J. Am. Med. Assoc. 240:1978;1963-1965.
26. Bodi M, Ardanuy C, Olona, et al. Therapy of ventilator-associated pneumonia - the Tarragona strategy, Clin. Microbiol. Inf. 2001;7:32-3.
27. Rochon-Edouard S., Pestel-Caron M., Lemeland J.-F., Caron F. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomycin and netilmicin against methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 44:2000;3055-3060.
28. Zavasky D.M., Sande M.A. Reconsideration of rifampicin: a unique drug for a unique infection. J. Am. Med. Assoc. 279:1990;1575-1577.
29. Burnie J., Matthews R., Jiman-Fatami A., et al. Analysis of 42 cases of septicaemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin. Infect. Dis. 31:2001;684-689.
30. Leggett J., Fantin B., Ebert S., et al. Comparative antibiotic dose effect relations at several dosing intervals in murine pneumonitis and thigh infection models. J. Infect. Dis. 159:1988;281-292.
31. Schentag J.J. Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit. Crit. Care Med. 29:(Suppl. 4):2001;N100-N107.
32. Wysocki M., Delatour F., Faurisson F., et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother. 45:2001;2460-2467.
33. Thekli G., Ellis R., Marshall J., et al. Pharmacokinetic and tissue penetration of linezolid multiple oral doses. Antimicrob. Agents Chemother. 45:2001;1843-1846.
34. Rubinstein E., Cammarata S.K., Oliphant T.H., et al. Linezolid (PNU100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind multicenter study. Clin. Infect. Dis. 32:2001;402-412.
35. Kollef M.H. Is there a role for antibiotic cycling in the intensive care unit? Crit. Care Med. Suppl. 29:2001;N135-N142.
36. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients, Clin. Infect. Dis. 2000;(Suppl. 4):31:S131-8.
37. Wilcox M, Tang T, Hafkin B. Linezolid versus teicoplanin for the treatment of hospitalized patients with Gram-positive infections. 41st Interscience Cong. Antimicrob. Agents Chemother., Chicago, IL, 2001 (Abstract 1481).